A Randomised, Double-blind, 4-week, Crossover Trial on Two Treatment Regimens With Biphasic Insulin Aspart 70 and 50 in Patients With Type 2 Diabetes

Novo Nordisk A/S1 site in 1 country16 target enrollmentMarch 1999

ConditionsDiabetes Diabetes Mellitus, Type 2

Interventionsbiphasic insulin aspart 50 biphasic insulin aspart 70

Drugsbiphasic insulin aspart 70 biphasic insulin aspart 50

Overview

Phase: Phase 3
Intervention: biphasic insulin aspart 50
Conditions: Diabetes
Sponsor: Novo Nordisk A/S
Enrollment: 16
Locations: 1
Primary Endpoint: Fasting serum glucose
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This trial is conducted in Europe. The aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.

Registry

clinicaltrials.gov

Start Date

March 1999

End Date

June 1999

Last Updated

9 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Novo Nordisk A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Type 2 diabetes
•Duration of diabetes for longer than 12 months
•Body mass index (BMI) below 35.0 kg/m\^2
•HbA1c below 11.0 %
•Treatment with BHI (biphasic human insulin) 20 or 30 twice daily for at least three months and in the last month as sole anti-diabetic treatment (i.e., no additional oral hypoglycaemic medication or daily use of short-acting insulin supplement)